Articles related to Family Medicine/General Practice

Navigating the Interplay of Eliquis and Dietary Habits As physicians, understanding the nuances of apixaban (Eliquis) and its interaction with diet is crucial for optimal patient care. While taking Eliquis, there are no specific foods to avoid, but people with cardiovascular issues should steer clear of coffee and foods heavy in fat.

Understanding COVID-19’s Cognitive Effects on College Students As physicians, understanding the cognitive effects of the COVID-19 pandemic on our younger population is crucial. This summary distills key findings from a recent study conducted by The Ohio State University.

The SSRI inhibitor was previously limited to adults. As physicians, we are continually seeking effective treatment options for our pediatric patients. The recent FDA approval of Lexapro for pediatric GAD treatment marks a significant advancement in this field.

Understanding Xylazine: The Rising Challenge in Opioid Crisis Management As physicians, it’s crucial to stay informed about emerging drug threats. Xylazine, a powerful livestock tranquilizer mixed into fentanyl, is one such threat that’s gaining momentum.

Insomnia is often underrecognized and undertreated in primary care settings. A panel of experts convened by Haymarket Medical Education emphasizes the importance of considering comorbid medical and psychiatric illnesses in patients with insomnia and recommends proactive screening and personalized treatment strategies. As a psychiatrist, neurologist, or other sleep disorder professional, you may often be on the front lines of managing insomnia, a condition that is increasingly prevalent yet remains underrecognized in primary care settings. A recent report by a panel of experts provides crucial insights and recommendations to enhance our approach to this pervasive sleep disorder:

Dive into how the FDA-approved Farxiga is changing the heart failure treatment landscape. Colleagues, let’s dive into a remarkable milestone. Farxiga, known as dapagliflozin, now has FDA approval. This is groundbreaking for heart failure treatment. It applies to all patients, regardless of their left ventricular ejection fraction (LVEF) status. The approval didn’t happen overnight. Let’s talk about the DELIVER trial, a vital part of the process. It involved over 6,000 patients, all over 40. Each had heart failure, LVEF above 40%, and may or may not have had type 2 diabetes. They took either dapagliflozin or a placebo daily, plus their usual therapy. The trial had a clear goal: time to the first composite event. This included CV death, heart failure hospitalization, or an urgent heart failure visit. The goal applied to everyone, including patients with LVEF less than 60%. Fast forward about 2.3 years, the results were significant. Dapagliflozin cut the composite outcome by 18% versus the placebo. Both worsening heart failure and CV death rates dropped in the dapagliflozin group. The best part? These findings were consistent, even in patients with lower LVEF or diabetes. Expanding the picture, let’s consider two trials together: DELIVER and DAPA-HF. Over 22 […]